A total of 40 to 50% of liver cancer has a clonal component that drives early tumor initiation and recurrence by a small population of tumor-initiating stem cell-like cells (TICs).
(1) The survival outcome of patients with hepatocellular carcinoma (HCC) is inversely correlated with the expression of CD133, the TIC marker appearing in advanced stages of the disease. (2, 3) In alcohol-associated and obesity-associated liver cancers, Toll-like receptor 4 is ectopically expressed and activated in TICs, leading to induction of Nanog and other pluripotent genes, self-renewal, and tumor-initiating activity. (4) (5) (6) Surgical resection and liver transplantation are the only efficacious treatments for early liver cancer and are applicable to only a fraction of patients. In patients with advanced HCC who are not surgical candidates, chemoembolization, local ablation, and systemic chemotherapy remain primary options. (7) However, HCC is often chemoresistant, and TICs are believed to contribute to this resistance. (1) The lack of understanding of biology concerning drug resistance in cancer constitutes an obvious hurdle for the development of an efficacious anticancer drug. (1) The only therapeutic agent currently approved for HCC is sorafenib, a Raf kinase inhibitor, but its clinical benefits are limited and not durable. (8, 9) The mammalian Target of Rapamycin (mTOR) pathway is one of the most well studied pathways in cancer, as it often is activated in tumors including HCC. (10, 11) Indeed, activation of mTOR pathway in transgenic (Tg) mice (12) is sufficient to cause HCC. Liver-specific deficiency of TSC1, the inhibitory GAP for Rheb, results in sustained activation of mTOR and development of liver tumors. (12) These studies prompted clinical trials of mTOR inhibitors such as rapamycin and its analogs, everolimus (RAD001), temsirolimus (CCI-779), and deforolimus (AP23573). In general, these mTORC1 inhibitors were tolerated well but had limited or no therapeutic benefits as demonstrated by a most recent multicenter randomized, double-blind phase III study with everolimus, which ended with the negative outcome. (13) In fact, inhibition of the mTORC1 pathway promotes liver tumorigenesis in the mouse model of DEN-induced liver cancer either through enhanced liver injury (14) or CD133 induction. (15, 16) Biological functions controlled by mTOR pathway are diverse, but the two most characterized functions are cell growth and autophagy suppression. Autophagy is a homeostatic mechanism that is essential for cellular fitness activated during stress, senescence, or compromised cell growth. (17) In cancer cells, autophagy serves as a survival mechanism from therapeutic treatment, manifested by chemoresistance. (17) Autophagy requires an orchestration of vesicle transport, (18) and damaged proteins and organelles are brought into autophagosomes through the microtubule-associated protein 1A/1B-light chain 3 (LC3) complex containing p62/SQSTM1. Under starvation or stress, LC3-I is conjugated with phosphatidylethanolamine (LC3-II) to facilitate the formation of autophagosomes. If damaged proteins are not transported to autophagosomes, p62/SQSTM1 accumulates in cells, aggravating endoplasmic reticulum stress.
As rapamycin analogs inhibit mTORC1 and in turn induce autophagy in cancer cells, we hypothesized that this effect must counteract the mTOR inhibitor's efficacy. In fact, autophagy inhibitors, such as chloroquine (CQ), synergize the cytotoxic effect of rapamycin analogs on cancer cells, (19, 20) suggesting that concomitant suppression of autophagy with growth inhibition of mTOR inhibitors is required. In search of a small molecule that abrogates chemoresistance of TICs, we identified baicalein (BC) as a bioactive small phytochemical that achieves this effect on mouse liver TICs and human HCC cells. In particular, BC's chemosensitizing effect is most pronounced with mTORC1 inhibition in vitro and in vivo, and this is because BC blocks autophagy stimulated by a mTORC1 inhibitor by interfering the GTP binding activity of SAR1B GTPase. Accordingly, the combination treatment with aRtICle INFoRMatIoN:
BC and temsirolimus (CCI-779) almost completely kills TICs and HCC cells but not primary hepatocytes and inhibits HCC growth in the patient-derived xenograft (PDX) model. Our study has identified a strategy to eliminate drug-resistant TICs by targeting SAR1B with a unique pharmacophore.
Materials and Methods

Cell CUltURe aND tReatMeNtS
Mouse liver TICs were originally isolated by fluorescence-activated cell sorting based on surface expression of CD133 and CD49f from liver tumors developed in hepatitis C virus (HCV) NS5A transgenic mice fed alcohol according to the protocol described previously (4) and later confirmed by isolation of similar TICs from HCV Core Tg mice fed alcohol, Spnb+/− mice, NS5A Tg mice fed Western diet (21) and HCC tissues excised from alcoholic HCV infected patients. (5) They were cultured and maintained as a cell line in Dubecco's modified Eagle medium (DMEM): Nutrient Mixture F-12 media (Life Technologies, Camarillo, CA) with 10% fetal bovine serum (FBS), 20 ng/mL murine endothelial growth factor (EGF; Peprotech, Rocky Hill, NJ), Embryomax nucleosides (MilliporeSigma, Burlington, MA), 100 nM dexamethasone (SigmaAldrich, St. Louis, MO), and antibiotic-antimycotic (Life Technologies). Huh7 cells were cultured and maintained in the same medium without EGF. To isolate primary hepatocytes, the liver of normal C57/ B6j mice ( Jackson Laboratory, Bar Harbor, ME) was digested with 0.04% weight-per-volume collagenase Type I, and hepatocytes were purified by centrifuging on Percoll. The hepatocytes were treated in the TIC medium without FBS. Frozen human hepatocytes (hHep) were obtained from the University of Kansas Liver Center. Induction-qualified cryopreserved hHEP were purchased from Thermo Fisher Scientific (#HMCPIS; Waltham, MA). All compounds used for treatment were purchased from Sigma-Aldrich, dissolved in dimethyl sulfoxide, aliquoted and kept frozen in −20 °C. 6,7-dihydroxy, 5-methoxyflavone was synthesized by WuXi Pharmatech (Shanghai, China). Yang-Gan-Wan (YGW) powder was suspended and vortexed briefly in serum-free DMEM-F12 medium. The soluble fraction was collected and diluted to 35 mg/mL in serum-free DMEM-F12. The extract was further diluted in TIC medium without serum for final treatment.
gUaNoSINe tRIpHoSpHate BINDINg aSSay
The cells were lysed in 0.25 mL of GTP binding buffer on ice after three freeze-thaw cycles as described previously. (22) The GTP-agarose (50 μL) (Sigma Aldrich) was added to each tube containing 0.25 mL of lysate and incubated at 4 °C for 1 hour by rotating. The input (the initial lysate), the unbound fraction (the lysate left after 1-hour incubation with GTPagarose), and GTP bound fraction were collected. The GTP bound proteins were denatured in 40 μL of 6× sodium dodecyl sulfate (SDS) sample buffer by boiling the beads for 10 minutes. The input and unbound fractions were denatured in 1× SDS sample buffer. The fractions were separated in the SDS gel andimmunoblotting was performed with indicated antibodies.
SpHeRoID FoRMatIoN aND CloNogeNIC aSSayS
The TICs (1000 cells) were suspended in serum-free TIC medium with 1% methylcellulose supplemented with B27, 20 ng/mL EGF, and 20 ng/mL fibroblast growth factor in each well of a 96-well ultralow attachment plate. The cells were treated with compounds for 7 days and colonies bigger than approximately 40 μm were enumerated. To measure drug-resistant cells, 1×10 5 cells were treated in spheroid formation conditions without methylcellulose for 7 days in the 96-well ultralow attachment plate (Corning, Corning, NY). At the end of the treatment, cells in 25 μL to 50 μL were replated in a regular 6-well tissue culture plate in TIC medium with 10% FBS for 5 to 7 days without any drugs. At the end of the treatment, the cells were fixed with methanol/acetic acid mixture (1:7) and stained with 1% crystal violet at room temperature. The crystal violet was extracted with 10% acetic acid and diluted with 4 fold of water. The amount of crystal violet was measured at 570 nm.
aFFINIty pURIFICatIoN oF tHe BlIN-BINDINg pRoteINS
Blin and the related compounds-fixed affinity nanobeads were prepared as previously described. (23) Briefly, Blin, rosmarinic acid, or carsonic acid was incubated at 1 mM or 5 mM with equal amounts of N-hydroxysuccinimide and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (Dojindo, Rockville, MD) for 2 hours at room temperature with amino-modified affinity beads. For purification of Blin-binding proteins, 0.2 mg of beads were equilibrated with the binding buffer (20 mM HEPES [pH 7.9], 100 mM NaCl, 1 mM MgCl 2 , 0.2 mM ethylene diamine tetraacetic acid, 10% glycerol, 0.1% NP40), and incubated with 0.2 mg/mL of TIC cell lysate or mouse liver cytosolic extract at 4 ºC for 1 hour. Bound proteins were eluted with SDS-loading dye, analyzed by SDS polyacrylamide gel electrophoresis, and then visualized by silver staining (Wako Chemicals USA, Richmond, VA). Bound proteins were subjected to in-gel digestion by trypsin, and the fragments of the peptides were analyzed by electrospray ionization mass spectrometry (Synapt G2; Waters Corp, Milford, MA). For competition assay, recombinant RAB1A protein (ATGen, Los Angeles, CA) was pre-incubated with indicated amounts of GTP or adenosine triphosphate (ATP) for 30 minutes, and then mixed with the BC-fixed nanobeads for 1 hour. Bound proteins were visualized by silver staining. 
patIeNt-DeRIVeD XeNogRaFt
StatIStICal aNalySIS
All statistical analyses and IC 50 values were determined by Prism Software (Graphpad, La Jolla, CA). Concentration of the compounds were log transformed and the IC 50 values were determined using Hill Plot analysis. Where appropriate, statistical comparison was performed by t-test, one-way or two-way analysis of variance (ANOVA) with Bonferroni posttest. Error bars indicate SEM of replicate experiments.
Results
BC SUppReSSeS SteMNeSS geNeS aND INDUCeS apoptoSIS oF lIVeR tICS
We used mouse liver CD133 + TICs isolated from HCV NS5A Tg mice as a model to screen small molecules that selectively kill TICs. These TICs have also been isolated from three other HCC animal models and patient HCC tissues, and characterized for their NANOG-dependent self-renewal and tumor-initiating activities, (4, 5) the leptin receptor (OB-R)-mediated OCT4 and SOX2 upregulation, (24) TWIST induction by NANOG and STAT cooperation, (21) NANOGmediated loss of p53 through NUMB phosphorylation, and NANOG-driven mitochondrial metabolic reprogramming. (25) We screened the aqueous extract of the herbal mixture YGW, which protects mouse livers from CCl4 hepatotoxicity, (26, 27) selectively kills TICs, and prevents DEN-induced liver tumor development (Supporting Figs. S1-S3). Our strategy used fractionation of the extract to test for selective toxicity toward TICs and for the ability to inhibit pluripotent genes and induce hepatocyte differentiation genes (Fig. 1A) . Fractions identified to possess peak activities of selective TIC cytotoxicity were subjected to nuclear magnetic resonance analysis for molecular identification (28) (Supporting Fig. S4 ). This analysis discovered that BC (5,6,7-trihydroxyflavone) is a main chemical responsible for selective cytotoxicity of TICs. We also identified wogonin (Wog, 5,7-dihydroxy-8-methoxy flavone) as having a similar activity. Having identified these two structurally similar flavones, we acquired several derivatives of BC as shown in Fig. 1B and tested them in TIC viability assay (Fig. 1C ). This analysis revealed that the TIC lethality was dependent on the polyphenolic structure (-OH) at C5-C7 and was reduced by decreasing these phenolic groups (Fig. 1B,C) . For example, BC with -OH at all C5-C7 positions has the highest potency (IC 50 = 7.3 μM); Wog with -OH at C5 and C7 (IC 50 = 13.8 μM), 6,7 dihydroxy, 5 metoxyflavone with -OH at C6 and C7 (IC 50 = 16.6 μM), or baicalin (Blin) with -OH at C5 and C6 has the intermediate killing effect (IC 50 = 48.9 μM); and trimethoxyflavone (TMF) with all -OH groups replaced with the methoxyl group has no activity (Fig. 1C) . Luteolin with -OH at C5 and C7 and an additional catechol -OH structure in a benzene at the side arm shows a similar potency (IC 50 = 6.22 μM) as BC against TICs, suggesting the importance of a catecholic group. Neither BC nor luteolin showed toxicity in normal mouse hepatocytes until the concentration reached 100 μM (Fig. 1D) . BC also selectively induced apoptosis markers in TICs but not in hepatocytes, such as caspase 3 cleavage and p-γH2AX formation (Fig. 1E) .
BC inhibited pluripotent (Nanog and Sox2) and EMT (Twist1 and Snai1) genes while upregulating hepatocyte differentiation genes (Cyp7a1 and Alb) ( Fig. 2A) and suppressed TIC self-renewal as evident by reduced spheroid formation (Fig. 2B) . These results suggested that BC preferentially reduces the viability of liver TICs by suppressing self-renewal and stemness. Pharmacokinetics and intracellular uptake assays showed that BC is an active compound in liver (Supporting Fig. S5 ), and hepatocytes convert BC to Blin more efficiently than TICs, whereas TICs' ability to convert Blin to BC is superior than hepatocytes (Supporting Fig. S5E-S5H ), providing a possible explanation for selective toxicity of BC on TICs over hepatocytes.
BC elIMINateS CD133 + tICS ReSIStaNt to MtoRC1 INHIBItIoN
We next tested the chemosensitizing effect of BC for therapeutic agents currently used for liver cancers: rapamycin, sorafenib, and doxorubicin. Although BC enhanced cytotoxicity of sorafenib and doxorubicin toward TICs (Supporting Fig. S6A,S6B ), its chemosensitizing effect on rapamycin was more pronounced (Supporting Fig. S6C ). The mTORC1 inhibitors induce the expression of CD133 in cancer cells and enrich CD133 + cancer cells, (15, 16) raising a possibility that this effect may cause the chemoresistance and limit the efficacy of anticancer drugs. Indeed, we found that a rapamycin analog, temsirolimus (CCI779), treatment induced CD133 in TICs and the human HCC Huh7 cells. However, cotreatment of BC completely prevented this induction (Fig. 2C,D) and synergistically promoted cytotoxicity of TICs (Supporting Fig. S6D ). BC and CCI779 cotreatment also suppressed other stemness genes such as Nanog and Sox2 in TICs (Supporting Fig.  S7 ). We also tested this BC effect in the spheroid culture condition, the condition that enhances drug resistance compared with two-dimensional culture. We treated TIC spheroids with BC in the presence or absence of CCI779 for 7 days and any surviving cells were replated in normal two-dimensional culture. The TIC spheroids were completely eliminated by the combination treatment of BC and CCI779, whereas some spheroids still remained after individual treatments (Fig. 3A) . When these remaining spheroids were replated, the resistant cells grew again in the culture dish. However, the combination treatment with BC and CCI779 eliminated these resistant cells as measured by the crystal violet staining (Fig. 3A) . To determine whether this combination effect is additive or synergistic, we calculated the combination index (CI) using the Chou-Talalay equation. (29) The CI was determined to be 0.58, verifying that the effect was synergistic. Furthermore, the BC treatment decreased the IC 50 value of CCI779 for TICs by 4.5 fold (Fig. 3B) . BC had a similar activity in human HCC Huh7 (Fig.  3C,D) and PLC/PRF/5 cells (Fig. 3E,F) , which were also resistant to mTORC1 inhibition. The combination of BC and CCI779 also enhanced caspase 3 cleavage in Huh7 cells compared with treatment of the individual compound (Supporting Fig. S8, left) , but neither compound induces caspase 3 cleavage in hHep (Supporting Fig. S8, right) .
BC BINDS aND INHIBItS SMall gtpaSeS INVolVeD IN VeSICle tRaNSpoRt
Next, we aimed to identify the molecular target of BC for the observed TIC cytotoxic effect. For this, we conjugated nanobeads onto Blin through its glucuronate moiety, which readily allowed this manipulation, whereas BC without this moiety could not be conjugated without disturbing the functional groups (Supporting Fig. S9 ). Although Blin is less potent than BC in TIC cytotoxicity assay, we anticipated that Blin's flavone backbone would still bind to the same target molecules as BC. We incubated the nanobead-conjugated Blin (B) with TIC or mouse liver lysate and pulled down associated proteins for gel display. Rosmarinic acid-nanobeads (R) and carsonic acidnanobeads (C) were used as negative controls. Silver staining identified protein bands only present with B. One corresponding to the molecular size of 26 kD in both liver and TIC lysate was cut out and subjected to mass spectrometry (Fig. 4A,B) , which identified RAB1B, RAB1B, SAR1B, RAB14, and RAN. All of these proteins have one common function: the transport of vesicles as GTPases.
Having identified the GTPases as potential targets, we next examined the expression and activity of these GTPases in TICs. Immunoblotting demonstrated that SAR1B, RAB1B, and RAN are expressed at high levels in TICs (the first lane of the left panel in Fig. 4C ). However, when we pulled down these proteins with GTP-agarose to assess their activities in TICs, (22) only SAR1B showed high activity but not RAB1A, RAB1B, RAB14 and RAN (the first lane of the right panel of Fig. 4C ), suggesting that in TICs, SAR1B is a major active GTPase. We then added BC, Blin, and TMF to TIC lysate to determine their effects on SAR1B activity. BC, but not Blin or TMF, reduced SAR1B binding of GTP-agarose (most upper blot of the right panel, Fig. 4C ), suggesting that BC interferes with GTP binding to SAR1B, the step required for its activity. To validate BC inhibition of SAR1B-GTP binding in intact TICs, TICs were treated with BC (30 μM) and cell lysate was analyzed for GTP-agarose binding. This analysis confirmed inhibition of SAR1B-GTP binding by BC (Fig. 4D) . Similarly, BC inhibited SAR1B-GTP binding in human HCC cell lines, Huh7 and PLC/ PRF/5 (Fig. 4E,F) . We also showed that the increasing concentration of GTP but not of ATP blocked the ability of Blin-nanobeads to pull down recombinant RAB1A protein (Supporting Fig. S10A ), suggesting the similar competition between GTP and Blin for RAB1A binding. In 293FT cells transduced with RAB1B, BC also reduced the amount of RAB1B pulldown by GTP-agarose (Fig. S10B) . Thus, RAB1B-GTP binding is also inhibited by BC in this cell-free or RAB1B-transduced cell lysate. However, as this GTPase is not as active as SAR1B in TICs, SAR1B most likely represents a primary target of BC in TICs.
We performed the three-dimensional computational modeling analysis to identify the possible mode of interactions between BC and SAR1B. (30, 31) The analysis revealed that BC binds to a pocket near a region known as STAR (Sar1-NH 2 -terminal activation recruitment) motif, a motif responsible for activation and its interaction with SEC12 GEF (guanine nucleotide exchange factor) (31) (Supporting Fig.  S10C ,D) through three critical amino acids, D47, M44 and Y186 (Supporting Fig. S10E) , with the weak binding energy of −5.53 kcal/mol. These data suggest that BC may interfere with the STAR-dependent functions including GEF binding, as well as GAP binding, inhibiting cyclic activation of SAR1B. In contrast, we discovered that BC's primary mode of RAB1B inhibition is through its interaction with the GTP binding site of RAB1B through five critical amino acids: Y33, C23, N121, D124, and K153 (Fig. S10F,G) . Y33 and C23 are conserved between RAB1A and RAB1B. N121, D124, and K153 residues, which are responsible for interacting with phenolic functional groups on BC, are conserved among various RAB proteins and SAR1B (Supporting Fig. S11 ), suggesting that SAR1B may also be targeted by the same mechanism. The free energy of BC binding to the guanine binding site of RAB1B is estimated to be −8.82 kcal. These data suggest that BC has different modes of inhibition on GTPases.
BC INHIBItS aUtopHagoSoMe FoRMatIoN StIMUlateD By mtoR INHIBItIoN
RAB1B and SAR1B are involved in the autophagosome formation. (32, 33) Therefore, we hypothesized that BC may inhibit autophagy. To test this notion, we measured in BC-treated TICs the level of p62/ SQSTM1 that accumulates when autophagy is suppressed. Indeed, both YGW and BC increased p62/ SQSTM1 after overnight treatment (Supporting Fig.  S12A ). BC increased p62/SQSTM1 more robustly than Blin, correlating with their relative anticancer activities (Fig. 5A) . We further analyzed the effects of BC on autophagic flux. For this analysis, we used the mTOR inhibitor CCI779 (temsirolimus) to activate autophagic signal and CQ to inhibit autophagic degradation by lysosomes and examined the lipidation of LC3 essential for autophagosome formation. Under basal condition in TICs, immunoblot analysis detected LC3I (unlipidated LC3) and less LC3II (lipidated LC3), and BC treatment reduced both LC3I and LC3II (Fig. 5B) . Chloroquine increased LC3II as expected from its inhibitory effect on lysosomal degradation. CCl779 alone or in combination with CQ caused disappearance of LC3I and increased LC3II, as evidenced by increased autophagic flux by mTOR suppression. However, BC abrogated this induction (Fig.  5B, left) , and this effect was also observed in Huh7 cells (Fig. 5B, right) , demonstrating that BC inhibits autophagosome formation. We also observed that BC increased p62/SQSTM1 even at lower concentrations when cotreated with CCI779 (Fig. 5C ). To confirm this finding on autophagy, we performed immunofluorescent microscopy for LC3 protein in TICs treated with BC versus vehicle with or without CCI779 and CQ. Punctate staining pattern of LC3 was induced by CCI779 and CQ as the evidence of autophagosome formation (Fig. 5D, upper right) , and this induction was abrogated by BC treatment (Fig. 5D, lower right) . Furthermore, the cytotoxic effect of CCI779 and BC on TICs was reproduced by the treatment with CCI779 and the autophagy inhibitor, CQ (Fig. 5E ), supporting the notion that autophagy inhibition renders a synergistic elimination of TICs treated with CCI779. BC and CQ cotreatment showed no toxicity (Fig. 5E ), supporting the idea that both autophagy inhibitory effects are not cytotoxic, but either chemical renders toxicity when autophagy is induced by CCI779. Our finding is also consistent with the proposal that inhibition of autophagy is necessary for eliminating drug-resistant CD133 + liver cancer cells.
BC elIMINateS HCC ReSIStaNCe to MtoRC1 INHIBItIoN
The combination effect of BC and CCI779 was also verified in an animal model, in which tumor growth after TIC implantation in nude mice was completely prevented (Supporting Fig. S13 ). To gain the translational relevance of this combination effect, we tested the combination treatment in NSG mice transplanted with HCC tissue resected from a NASH patient and showed a complete prevention of tumor growth by the combination treatment (Fig. 6A ). This therapeutic effect was accompanied by marked induction of tumor cell death (Fig. 6B,C) . LC3II, the indicator of autophagosome formation, was also reduced in HCC of the mice with the combination treatment (Fig. 6D) . Similar to BC's effects on cells, BC-treated tumor tissues showed significant reduction of active SAR1B (decreased GTP-bound SAR1B over total SAR1B) as determined by immunoblotting and densitometric quantitation (Fig. 6E) . Collectively, these results support the notion that the combination treatment prevents HCC growth by suppressing autophagy and chemosensitizing tumor cells.
BC eFFeCtS aRe RepRoDUCeD By SaR1B KNoCKDoWN aND ReSCUeD By SaR1B eXpReSSIoN
Because SAR1B is the putative target of BC and highly active in TICs, we next tested whether loss or overexpression of SAR1B affects TIC's and the BC's effects. SAR1B knockdown (KD) by two independent short-hairpin RNAs (shRNAs) in TICs partially prevented LC3II formation induced by CCI779 (Fig.  7A) , supporting the participation of SAR1B in autophagosome formation. When hemagglutinin (HA)-tagged SAR1B is expressed in TICs, BC inhibition of LC3II was rescued (Fig. 7B) , supporting that SAR1B is the BC's target for suppressed autophagosome formation. Finally, SAR1B KD but not RAB1B KD sensitized TICs for CCI779 cytotoxicity, with the IC 50 value reduced 28% as compared with TICs with scrambled shRNA (Fig. 7C) , suggesting that loss of SAR1B phenocopies BC's cytotoxic effect on CCI779-treated TICs. Expression of HA-SAR1B in TICs partially rescued the lethality induced by BC and CCI779 (Fig. 7D) , further supporting that SAR1B targeted by BC mediates TIC killing by the combination treatment. RAB1B KD suppressed CCI779-induced LC3II (Supporting Fig. S14A ) and RAB1 overexpression rescued BC-mediated inhibition of CCI779-induced LC3II (Supporting Fig.  S14B ). However, overexpression of RAB1B did not rescue TIC killing by the combination treatment (Supporting Fig. S14C ).
aBUNDaNt SaR1B May pRoteCt HepatoCyteS FRoM BC'S aCtIoN
BC exerted no toxicity to normal mouse hepatocytes (Fig. 1E) . Furthermore, the combination treatment of BC (60 μM) and escalating concentration of CCI779 for 5 days rendered no cytotoxicity in cultured mouse hepatocytes (Fig. 8A, left) and hHep (Fig. 8A, right) in contrast to dose-dependent cell death in TICs and Huh7 cells as assessed by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay. These results are also corroborated by Caspase 3 activation analysis (Supporting Fig. S8 ). To determine the role of SAR1B in the sensitivity of cancer cells and hepatocytes to BC, we checked the levels of active SAR1B (GTP bound) and total SAR1B in TICs versus mouse hepatocytes (mHep), human HCC Huh7 and PLC/ PRF/5 cells versus human hepatocytes (hHep). We found that both GTP-bound SAR1B and total SAR1B were higher in mHep and hHep compared with the cancer cells (Fig. 8B ) and these differences correlated with higher basal levels of LC3II in hepatocytes (Fig. 8C) . These data may just reflect higher activities of the GTPase and autophagosome formation required for functions of the differentiated cells but may also make Immunoblot analysis revealed that LC3II in HCC was decreased by the combination treatment, suggesting suppressed autophagosome formation. One-way ANOVA was used to calculate the statistical significance. (E) Active SAR1B was pulled down using GTP-agarose from tumor tissues from PDX mice-treated vehicle or BC and CCI-779. Densitometric analysis was performed and GTPSAR1B/totalSAR1B values were calculated. Student's t-test was used to calculate the statistical significance. Error bars indicate the SEM of replicate measurements. **P < 0.01 and *P < 0.05. them less sensitive to the effect of BC or BC plus CCI779 due to abundant active SAR1B.
Discussion
Phase III clinical trials for mTORC1 inhibitors in liver cancer have experienced limited therapeutic benefits, suggesting that the resistance to mTORC1 inhibitors may exist in HCC and a conjunctive therapy with another drug may be needed. To this end, a combination of sorafenib and mTORC1 inhibitor was evaluated for HCC in clinical trials, but showed severe toxicities. (35) We hypothesized that induction of CD133 (15, 16) and autophagy by mTORC1 inhibitors might have contributed to the chemoresistance in cancer cells treated with these drugs. Indeed, our research demonstrates that BC abrogates induction of both CD133 and autophagy by CCI779, and chemosensitizes TICs and HCC cells to CCI779 while having no toxicity in primary hepatocytes. This new pharmacologic feature of BC adds to liver protective properties previously shown for BC or BC-containing herbal preparation in the experimental mouse models. (26, 27, (36) (37) (38) Feeding the herbal preparation with BC as an active component to mice for longer than a year causes no obvious toxicity (Supporting Fig. S2 ) but effectively suppresses liver cancer formation (Supporting Fig. S3 ). In a phase I clinical study, BC is found safe with no signs of liver or kidney toxicity even at the maximum dose of 2.8 g per individual.
(39) Therefore, BC may be considered a safe and effective adjuvant to mTORC1 inhibition in the treatment of liver cancer. In support of this notion, the combination treatment of BC and CCI779 showed impressive killing of HCC cells and complete abrogation of HCC growth in the PDX model. BC offers various therapeutic effects, (40) but its molecular targets have not been fully established. BC may affect lipoxygenase activity, (41) but its molecular basis is poorly understood. Our unbiased approach of affinity purification of BC-associated proteins by nanobeads revealed its targets. The current study demonstrates that SAR1B is a putative BC target and that BC-mediated suppression of SAR1B-dependent autophagy induced by CCI779 underlies its chemosensitizing effect. In fact, SAR1B KD phenocopied the chemosensitizing effect of BC, and conversely, SAR1B expression rescued both inhibition of autophagy and cell death caused by BC and CCI779. We also identified RAB1 as a BC target in the cell-free system. However, RAB1B overexpression rescued BC-induced inhibition of LC3II but not cell death in CCI779-treated TICs, dissociating the effects on autophagy and cytotoxicity. These differential effects may be due to a possibility that SAR1B, which is a major active GTPase among several other GTPases including RAB1B in TICs, can easily compensate for loss of RAB1B. It is also highly likely that SAR1B may have additional unique functions that are critical for TIC or tumor cell survival that RAB1B cannot fulfill.
Selective sensitivity of TICs and HCC cells over primary hepatocytes is an intriguing finding. Our results suggest that this may be due to the different pharmacokinetic properties of TICs versus hepatocytes: TICs converting Blin to more toxic BC more efficiently than hepatocytes and hepatocytes converting BC to less toxic Blin more efficiently (Supporting Fig. S5F-H) . Secondly, TICs have SAR1B as a major active GTPase, whereas hepatocytes have higher expression of SAR1B and other GTPases in the active form, making hepatocytes more resistant to BC's antagonistic action toward SAR1B. In conclusion, our study identified SAR1B GTPase as a drug-resistant effector of TICs and HCC cells, which can be targeted by BC to chemosensitize them to mTORC1 inhibitors through a combination therapy.
